Abstract PS3-09-08: Five-year analysis of distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC)

作者
S.A. Hurvitz,Michal Jarzab,Alistair E. Ring,P. Sharma,Ionut Temciuc,H. Hu,Murat Akdere,Juan Pablo Zarate,Denise Aysel Yardley
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (4_Supplement): PS3-09
标识
DOI:10.1158/1557-3265.sabcs25-ps3-09-08
摘要

Abstract Background: Despite improvements in outcomes in patients with HR+ EBC, distant recurrence remains a major concern given that there is no cure for metastatic breast cancer. The NATALEE trial has shown invasive disease-free survival and DDFS benefits with RIB + NSAI in patients with stages II and III HR+/HER2− EBC. We present updated DDFS data from the prespecified 5-y landmark analysis of NATALEE across clinically relevant subgroups. Methods: In NATALEE, patients were randomized 1:1 to receive either RIB (400 mg/d, 3 wk on/1 wk off for 3 y) + NSAI (anastrozole 1 mg/d or letrozole 2.5 mg/d for ≥5 y) or NSAI alone; men and premenopausal women also received goserelin. Patients with anatomic stage IIA (either node-negative [N0] with additional risk factors or N1 [1-3 axillary lymph nodes]), IIB, or III disease per AJCC (8th edition) were included in the trial. DDFS, a secondary endpoint, was defined as the time from randomization to the first event of distant recurrence, second primary non-breast invasive cancer (except for basal and squamous cell skin carcinomas), or death from any cause. Kaplan-Meier analysis was used to estimate survival rates at each time point, and a Cox proportional hazards model was applied to calculate hazard ratios (HRs) for RIB + NSAI vs NSAI alone, stratified based on study stratification factors. DDFS was analyzed across clinically relevant subgroups, including anatomic stage and nodal status. Results: At the updated data cutoff of May 28, 2025, with a median duration of follow-up for DDFS of 55.5 months, RIB + NSAI continued to show a DDFS benefit (HR, 0.709 [95% CI: 0.608-0.827]; nominal 1-sided P<.0001) and a distant recurrence-free survival benefit (HR, 0.699 [95% CI: 0.594-0.824]; nominal 1-sided P<.0001) over NSAI alone in the intent-to-treat population. The most common sites of distant recurrence were bone, liver, lung/pleura, and lymph nodes with fewer events observed with RIB + NSAI vs NSAI alone across all sites. The DDFS benefit was observed irrespective of anatomic stage (stage IIA [n=1001]: HR, 0.374 [95% CI: 0.218-0.644]; stage IIB [n=1045]: HR, 0.863 [95% CI: 0.580-1.285]; stage IIIA [n=1830]: HR, 0.735 [95% CI: 0.569-0.951]; stage IIIB [n=317]: HR, 0.644 [95% CI: 0.390-1.063]; stage IIIC [n=892]: HR, 0.785 [95% CI: 0.594-1.037]). Likewise, a consistent improvement in DDFS with RIB + NSAI vs NSAI alone was observed irrespective of nodal status (N0 [n=614]: HR, 0.539 [95% CI: 0.318-0.913]; node-positive [N+] [n=4479]: HR, 0.723 [95% CI: 0.615-0.849]). The DDFS benefit with RIB + NSAI vs NSAI alone was similar across other clinically relevant subgroups, which included subgroups based on menopausal status, age, prior endocrine therapy duration, and Ki-67 status. Conclusions: In this prespecified 5-y analysis, with all patients off RIB treatment for a median of 2 y, the DDFS benefit with RIB + NSAI was sustained or improved compared with prior NATALEE analysis. This benefit was observed across all key subgroups, including N0 disease. These findings support the use of adjuvant RIB + NSAI to reduce distant recurrence risk in the NATALEE-eligible high-risk HR+/HER2− EBC population. Citation Format: S. Hurvitz, M. Jarzab, A. Ring, P. Sharma, I. Temciuc, H. Hu, M. Akdere, J. Pablo Zarate, D. Yardley. Five-year analysis of distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-09-08.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
情怀的应助被wy采纳,获得10
1秒前
2秒前
3秒前
3秒前
4秒前
5秒前
天天快乐的应助被pivot_literature采纳,获得10
5秒前
5秒前
喵喵完成签到,获得积分10
6秒前
6秒前
虚幻的香彤完成签到,获得积分10
7秒前
7秒前
taik发布了新的文献求助10
7秒前
866发布了新的文献求助10
7秒前
111发布了新的文献求助10
7秒前
ISSING完成签到,获得积分10
9秒前
9秒前
9秒前
YYY发布了新的文献求助10
9秒前
10秒前
happy的应助被tszjw168采纳,获得10
10秒前
wy发布了新的文献求助10
11秒前
Rina发布了新的文献求助10
11秒前
12秒前
LImin发布了新的文献求助10
12秒前
XIAOXIAO完成签到,获得积分10
14秒前
蕊蕊发布了新的文献求助10
14秒前
刘留流六发布了新的文献求助10
14秒前
乘风的法袍完成签到,获得积分10
15秒前
15秒前
kali发布了新的文献求助10
15秒前
沃柑发布了新的文献求助10
16秒前
16秒前
17秒前
AshCoCo发布了新的文献求助10
17秒前
hucai完成签到,获得积分10
17秒前
18秒前
李存发布了新的文献求助10
18秒前
华仔的应助被德烁采纳,获得10
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192968
求助须知:如何正确求助?哪些是违规求助? 9579365
关于积分的说明 21864799
捐赠科研通 7792532
什么是DOI,文献DOI怎么找? 3437120
关于科研通互助平台的介绍 2560661
邀请新用户注册赠送积分活动 2483960